Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study


High-dose interleukin-(IL-2) has been broadly studied in tumour therapy, yet it may be inhibitory to T-cell-dependent immunity. Therefore immune and tumour responses mediated by low-dose IL-2 were studied systematically with respect to the feedback organisation of immune responses. IL-2 was administered once daily at three dose levels: 0.18, 0.9, 4.5 MIU/m2… (More)
DOI: 10.1007/BF01518453

7 Figures and Tables


  • Presentations referencing similar topics